NASDAQ:PTGX - Protagonist Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.00
  • Forecasted Upside: 43.13 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$26.55
▼ -0.08 (-0.30%)
1 month | 3 months | 12 months
Get New Protagonist Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTGX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$38.00
▲ +43.13% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $38.00, with a high forecast of $53.00 and a low forecast of $27.00. The average price target represents a 43.13% upside from the last price of $26.55.
Buy
The current consensus among 7 polled investment analysts is to buy stock in Protagonist Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $36.00High
i
3/11/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $36.00High
i
3/9/2021SVB LeerinkBoost Price TargetOutperform$30.00 ➝ $41.00Low
i
3/3/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$30.00 ➝ $41.00High
i
1/6/2021JPMorgan Chase & Co.Initiated CoverageOverweight$35.00N/A
i
12/16/2020Piper SandlerInitiated CoverageOverweight$53.00N/A
i
12/7/2020BMO Capital MarketsBoost Price Target$37.00 ➝ $46.00High
i
9/18/2020HC WainwrightBoost Price TargetBuy$28.00 ➝ $33.00High
i
7/15/2020Jefferies Financial GroupInitiated CoverageBuy$27.00High
i
5/22/2020SVB LeerinkBoost Price TargetOutperform$17.00 ➝ $30.00High
i
5/13/2020HC WainwrightReiterated RatingBuy$23.00 ➝ $28.00Low
i
5/11/2020NomuraBoost Price TargetBuy$29.00 ➝ $33.00Medium
i
5/11/2020Nomura InstinetBoost Price TargetBuy$29.00 ➝ $33.00Medium
i
8/13/2019SVB LeerinkReiterated RatingOutperformMedium
i
Rating by J. Schwartz at SVB Leerink LLC
8/11/2019Nomura SecuritiesReiterated RatingBuy$29.00Low
i
8/2/2019HC WainwrightSet Price TargetBuy$23.00Low
i
Rating by Douglas Tsao at HC Wainwright
7/8/2019HC WainwrightInitiated CoverageBuy ➝ Buy$23.00High
i
Rating by D. Tsao at HC Wainwright
5/8/2019Stifel NicolausUpgradeHold ➝ Buy$11.00 ➝ $17.00High
i
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$17.00Medium
i
12/6/2018Nomura SecuritiesInitiated CoverageBuy ➝ Buy$13.00Low
i
8/6/2018SVB LeerinkBoost Price TargetOutperform$13.00 ➝ $21.00High
i
6/6/2018BarclaysDowngradeOverweight ➝ Equal Weight$18.00Low
i
3/26/2018BMO Capital MarketsReiterated RatingBuy ➝ Outperform$42.00 ➝ $13.00Low
i
3/26/2018Stifel NicolausDowngradeBuy ➝ HoldMedium
i
3/8/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$44.00 ➝ $42.00Low
i
1/29/2018Stifel NicolausInitiated CoverageBuy ➝ Buy$32.00High
i
11/7/2017BMO Capital MarketsBoost Price TargetOutperform$40.00 ➝ $43.00N/A
i
10/19/2017BMO Capital MarketsLower Price TargetOutperform$45.00 ➝ $40.00N/A
i
7/21/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$36.00Medium
i
5/31/2017BMO Capital MarketsBoost Price TargetOutperform$34.00 ➝ $45.00High
i
11/18/2016BMO Capital MarketsReiterated RatingOutperform$21.00 ➝ $34.00N/A
i
9/6/2016BMO Capital MarketsInitiated CoverageOutperformN/A
i
9/6/2016SVB LeerinkInitiated CoverageOutperform$17.00N/A
i
Rating by J. Schwartz at SVB Leerink LLC
9/6/2016BarclaysInitiated CoverageOverweight$18.00N/A
i
(Data available from 4/18/2016 forward)
Protagonist Therapeutics logo
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More

Today's Range

Now: $26.55
$25.88
$26.94

50 Day Range

MA: $27.89
$23.57
$31.15

52 Week Range

Now: $26.55
$6.13
$32.10

Volume

212,728 shs

Average Volume

368,796 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Protagonist Therapeutics?

The following equities research analysts have issued research reports on Protagonist Therapeutics in the last year: BMO Capital Markets, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Nomura, Nomura Instinet, Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for PTGX.

What is the current price target for Protagonist Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Protagonist Therapeutics in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 43.1%. Piper Sandler has the highest price target set, predicting PTGX will reach $53.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $27.00 for Protagonist Therapeutics in the next year.
View the latest price targets for PTGX.

What is the current consensus analyst rating for Protagonist Therapeutics?

Protagonist Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTGX will outperform the market and that investors should add to their positions of Protagonist Therapeutics.
View the latest ratings for PTGX.

What other companies compete with Protagonist Therapeutics?

How do I contact Protagonist Therapeutics' investor relations team?

Protagonist Therapeutics' physical mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company's listed phone number is 510-474-0170 and its investor relations email address is [email protected] The official website for Protagonist Therapeutics is www.protagonist-inc.com.